Clinical Trials Logo

Glabellar Frown Lines clinical trials

View clinical trials related to Glabellar Frown Lines.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06411002 Recruiting - Clinical trials for Glabellar Frown Lines

Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines

Start date: April 8, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL). Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent. The primary objective of this study is to determine the efficacy and safety of the combined treatment of two upper facial regions with DAXI for injection.

NCT ID: NCT05481931 Recruiting - Clinical trials for Glabellar Frown Lines

Non Interventional Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines

Start date: March 15, 2023
Phase:
Study type: Observational

Non-interventional PASS of NUCEIVA for the treatment of moderate-to-severe glabellar lines to provide additional characterisation of the long-term safety of NUCEIVA in the real-world clinical practice setting.

NCT ID: NCT05083286 Recruiting - Clinical trials for Glabellar Frown Lines

Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Start date: October 20, 2021
Phase: Early Phase 1
Study type: Interventional

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.